The company’s technology delivers an anti-inflammatory agent directly to overreactive neutrophils, minimizing harm from “cytokine storms.”

The post U-M spinout Asalyxa Bio developing inflammatory treatment platform, aiding COVID-19 patients appeared first on Michigan Engineering News.